# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just repo...
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infecti...
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and...
Truist Securities analyst Robyn Karnauskas maintains Merck & Co (NYSE:MRK) with a Buy and raises the price target from $...
Wall Street suffers a double blow in Thursday’s session, as softer-than-expected revenue forecasts from Meta Platforms Inc. (NA...
Merck reported Q1 sales of $15.8 billion, beating estimates, with cancer drug Keytruda driving growth. Company raised full-year...